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Background: The prevention of type 2 diabetes is a globally recognised health care priority, but there is a lack of
rigorous research investigating optimal methods of translating diabetes prevention programmes, based on the
promotion of a healthy lifestyle, into routine primary care. The aim of the study is to establish whether a pragmatic
structured education programme targeting lifestyle and behaviour change in conjunction with motivational
maintenance via the telephone can reduce the incidence of type 2 diabetes in people with impaired glucose
regulation (a composite of impaired glucose tolerance and/or impaired fasting glucose) identified through a
validated risk score screening programme in primary care.
Design: Cluster randomised controlled trial undertaken at the level of primary care practices. Follow-up will be
conducted at 12, 24 and 36 months. The primary outcome is the incidence of type 2 diabetes. Secondary outcomes
include changes in HbA1c, blood glucose levels, cardiovascular risk, the presence of the Metabolic Syndrome and
the cost-effectiveness of the intervention.
Methods: The study consists of screening and intervention phases within 44 general practices coordinated from a
single academic research centre. Those at high risk of impaired glucose regulation or type 2 diabetes are identified
using a risk score and invited for screening using a 75 g-oral glucose tolerance test. Those with screen detected
impaired glucose regulation will be invited to take part in the trial. Practices will be randomised to standard care or
the intensive arm. Participants from intensive arm practices will receive a structured education programme with
motivational maintenance via the telephone and annual refresher sessions. The study will run from 2009–2014.
Discussion: This study will provide new evidence surrounding the long-term effectiveness of a diabetes prevention
programme conducted within routine primary care in the United Kingdom.
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Type 2 diabetes mellitus (T2DM) represents one of the
greatest global public health challenges in the 21st century
[1]. High glucose levels are currently recognised as the third
leading cause of mortality globally and treatment accounts
for 7-14% of total health care spending across all global
regions [2,3]. International and national health care organi-
sations have responded to this urgent health care need by
focusing on recommendations and policy aimed at preven-
tion. In the United Kingdom, this has taken the form of the
NHS Health Checks programme which is aimed at screen-
ing all individuals between 40 to 75 years of age for vascular
and metabolic disease risk and then treating high risk indi-
viduals accordingly [4]. Preventing T2DM is one of the fun-
damental aims of this programme. However in the UK, as
in many other parts of the globe, translational research has
lagged behind policy change and there has been a lack of
diabetes prevention programmes specifically developed for,
and evaluated in, routine health care settings.
Although large and well conducted randomised con-
trolled trials have consistently shown that lifestyle inter-
ventions can reduce the risk of progressing to T2DM by
30 to 60% in those with impaired glucose tolerance
(IGT), an intermediary high risk state between normal
glucose regulation and T2DM [5], there is no data from
the UK. There also remain important gaps in the evi-
dence when it comes to translating diabetes prevention
research into practice [6]. The majority of tested lifestyle
intervention studies have used intensive behaviour
change strategies relying on multiple and lengthy one-to-
one patient contacts which would be unsustainable in a
routine health care setting due to cost and infrastructure
limitations. Several countries have responded to this
limitation by developing, evaluating and implementing
diabetes prevention programmes that have been tailored
to the needs of their specific health care settings [7]. Al-
though these programmes have varied in context and
scope, they have consistently settled on utilising group-
based educational programmes as the primary vehicle for
promoting behaviour change [8-11]. A recent pilot study
in the UK added to these international developments by
demonstrating that a 3-hour structured education
programme was highly effective at promoting behaviour
change, improving glucose regulation and reducing the
risk of T2DM in those with IGT at 12 months which
were sustained at 24 months [12,13]. In the UK, struc-
tured education is already a widely advocated method of
promoting self-management strategies and a healthy life-
style in individuals with T2DM and forms an essential
component in integrated diabetes management pathways
nationally [14,15]. For example, the established DES-
MOND programme for individuals with T2DM is deliv-
ered nationally and internationally as part of routine care
and has been shown to be highly cost-effective [16].Given the current focus on prevention, there is consider-
able potential and interest for extending the educator
training and quality assurance infrastructure that have
accompanied programmes focused on diagnosed chronic
disease to the prevention of T2DM. However, this ap-
proach needs to be rigorously evaluated when conducted
in a primary health care setting.
Another potential limitation when considering the trans-
lation of diabetes prevention programmes into “real world”
settings is the disconnection between the population used
in traditional diabetes prevention programmes and routine
clinical practice. Diabetes preventions programmes have
typically included individuals on the basis of an oral glucose
tolerance test (OGTT) and the presence of IGT [5]. How-
ever, such tests may not be appropriate for universal screen-
ing given they are costly, time consuming and inconvenient
[17]. Both patients and health care professionals have
reported that the OGTT is a barrier to attending screening
[18]. Additionally studies have shown a low up-take to
screening with an OGTT [19] and participation in targeted
screening programmes is generally higher [20,21]. Therefore
pragmatic alternatives are required. Current international
consensus favours a stepped approach whereby high risk
individuals are identified using risk score technology which
is followed by a blood test to confirm high risk status and
rule out the presence of T2DM [22]. Those confirmed with
a high risk status can then be referred to a prevention
programme. However, the effectiveness and cost-effective-
ness of combining a stepped screening strategy with a be-
haviour intervention has not been evaluated in a usual
health care setting; this greatly limits the ability of health
care commissioners to make informed decisions when allo-
cating resources. This study will address these points by
screening those deemed at high risk of T2DM using a risk
score and recruiting those found to have Impaired Glucose
Regulation (IGR, a composite of IGT and/or impaired fast-
ing glucose (IFG)) into a prevention programme, and then
by formally assessing the cost-effectiveness of this strategy.Aim
The aim of the study is to establish whether a pragmatic
structured education programme targeting lifestyle and be-
haviour change in conjunction with motivational mainten-
ance via the telephone is cost-effective and can reduce
T2DM incidence in people with IGR identified through a
two stage screening programme in primary care.Methods/Design
The study consists of two phases. A screening phase where
people at risk of IGR/T2DM are identified using a validated
risk tool and secondly an intervention phase where those
identified with IGR will be recruited in to a T2DM preven-
tion cluster randomised trial.
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Identification of those at high risk of having IGR/T2DM
All participating GP practices will receive a Practice Pack
giving them general information and contact numbers for
the study. All practices will have an induction visit from the
project lead and research assistant who will provide training
and support.
An automated risk score will be used to identify those at
high risk of IGR/T2DM using data routinely stored on indi-
vidual GP practice computer databases. Various risk scores
have been developed and validated for identifying T2DM
[23]. Scores available to date have not been validated for the
UK multiethnic population and do not additionally pick up
those with IGR. Therefore we will use a score developed
using data from a previous screening study carried out in
Leicester [24]. This score has been amended to take into ac-
count ethnicity using the percentage of South Asians within
the practice as a proxy for individual ethnicity.
Before the risk tool is applied to a practice database
the quality of the data completion is assessed. If the
quality level of Body Mass Index (BMI) data recorded is
less than 40% practices will be asked to increase this be-
fore the risk tool can be used. The score will be calcu-
lated for all members of a participating practice. The
practice list will then be ranked by risk score with those
with the highest scores having the highest risk. The top
10% of patients with the highest score will be invited ini-
tially for screening. This 10% limit can be increased to
generate further invitations and increase inclusion in the
study if required. Where the top 10% of the risk score
identifies fewer than 500, all patients within the top 10%
will be invited. Where the number of eligible patients
identified in the top 10% is greater than 500, the first
500 patients within the top 10% will be invited. If the re-
sponse rate to initial invitations is insufficient a second
mailing of invitations will be conducted. A computer
programme will be written to automate the process and
produce an excel spreadsheet listing risk scores in des-
cending order.
The invitation will include a patient information sheet
and a reply sheet, so patients can register their interest in
taking part in the study. A self addressed envelope will be
provided for returning of slips. Patients will also be given
the number of a dedicated phone line to contact if they are
interested and/or require further information. Written
informed consent will be taken from all participants and
participants will be able to withdraw from the study at any
time.
Inclusion criteria
Patients are invited for screening if they fulfill the follow-
ing criteria:
 High risk according to a validated practice risk tool Aged 40 to 75 years if English speaking European or
25–75 years if South Asian
Exclusion criteria
Patients are excluded from the study if they are/have:
 Unable to give informed consent
 Pregnant or lactating
 Established diabetes
 Terminal illness
 Require an interpreter for language other than South
Asian
Baseline screening visit
Participants will be asked to fast for 8 hours prior to
attending the screening appointment and to bring a list
of prescribed medications with them. Before beginning
the overnight fast participants are asked to consume
their regular evening meal and take any medication as
normal. All participants receive a standard 75 g OGTT
following informed consent being taken. Those patients
who do not wish to have an OGTT will be discontinued
from the study and return to their GP for routine care.
Plasma samples are obtained immediately before (fasting
plasma glucose) and 120 minutes after the glucose chal-
lenge (two hours post challenge glucose) along with fast-
ing samples for serum urea and electrolytes, liver
function, lipids (total cholesterol, LDL-cholesterol, HDL-
cholesterol, triglycerides), and HbA1c. A number of bio-
markers will also be measured including: tumor necrosis
factor-α, interleukin-6, leptin, adiponectin, resistin, hs-
CRP, and PAI-1. Insulin resistance will be measured
using HOMA-IR. Levels of vitamin D and C will also be
measured.
Results will be relayed via written correspondence and
copied to participant and general practitioner. All bio-
chemical measurements will be performed in-house at
the University Hospitals of Leicester NHS Trust, UK.
Glucose samples will be taken in fluoride oxalate test
tubes and placed immediately in a portable 4 litre 4°C re-
frigerator. HbA1c% will be analysed by a DCCT aligned
Biorad Variant HPLC II system (Bio-Rad laboratories,
Hemel Hempstead, UK). The imprecision coefficient of
variation of this machinery is <0.1%, and the reference
intervals fit with national recommendations valid for car-
riers of variant Hb S, C and Q. Samples will be processed
within a maximum of two hours, using an Abbott Aero-
set clinical chemistry analyser (Abbott laboratories,
Maidenhead, UK), which employs the hexokinase enzym-
atic method. This machinery has an imprecision coeffi-
cient of variation of 1.61%. Serum total cholesterol, HDL-
cholesterol, LDL-cholesterol and triglycerides will be
measured by means of enzymatic techniques (Dade Behr-
ing Dimension analyser, Newark, USA). Plasma creatinine
Gray et al. Cardiovascular Diabetology 2012, 11:56 Page 4 of 10
http://www.cardiab.com/content/11/1/56will be analysed with kinetic colorimetric methods.
Plasma levels of urea and electrolytes, bilirubin, alanine
aminotransferase, alkaline phosphatase and thyroid
stimulating hormone will be analysed by means of the
Dade Behring Dimension analyser.
Participants will be categorised according to World
Health Organisation (WHO) criteria [25]. Diabetes will
be defined as a fasting blood glucose of greater or equal
to 7 mmoll-1 and/or 2 hour plasma glucose of greater
than or equal to 11.1 mmoll-1. Anyone who has an
OGTT result in the diabetes range will be recalled as
soon as possible for a second, confirmatory test for dia-
betes. Those found to have diabetes at baseline will dis-
continue the study and receive standard diabetes care
from their general practitioner; those found to have dia-
betes during follow up will remain in the study (but not
receive OGTTs, further follow up education or support
phone calls) and again be referred to their general practi-
tioner for their diabetes care. In this study IGR or ‘pre-
diabetes’ will be defined as IFG and/or IGT. IFG will be
defined as a fasting blood glucose concentration of be-
tween 6.1 and 6.9 mmoll-1 inclusive and IGT as a 2-hour
blood glucose concentration of between 7.8 and 11
mmoll-1 inclusive.
Anthropometric measurements will be performed by
trained staff using standard operating procedures. BMI
will be calculated after the body weight (kg) and height
(m) are measured, weight to be measured in light clothing
without shoes to the nearest 0.5 kg. Waist circumference
will be measured with a soft tape on standing participants,
mid-way between the lowest rib and iliac crest to the
nearest 0.1 cm. Hip circumference will be measured over
the widest part of the gluteal region, and the waist-to-hip
ratio calculated. Three blood pressure recordings will be
obtained from the right arm of the patient in a sitting pos-
ition after 3 minutes of rest, at 1 minute intervals, and
then the mean value will be calculated of the second and
third reading discounting the first. Seven day step count
will be assessed by giving all participants a sealed piezo-
electric pedometer (NL-800). Participants will be asked to
wear the pedometer, fitted to their trunks (placed on right
anterior axillary line) for seven consecutive days during
waking hours. Participants will be provided with a
stamped addressed envelope to return the pedometers to
the study co-ordinators.
A trained nurse will collect data on previous and
current medical history, medication and family history
using a standard form. Self completed questionnaires will
be used to assess smoking status, alcohol consumption,
occupation, sleep habits and ethnicity. Social deprivation
will be determined by assigning an Index of Multiple
Deprivation (IMD) score to participant postcodes [26].
IMD scores are publicly available continuous measures
of compound social and material deprivation which arecalculated using a variety of data including current in-
come, employment, health, education, and housing.
The following validated questionnaires will also be col-
lected
 The Dietary Instrument for Nutrition Education or
DINE food frequency questionnaire will be used to
assess dietary fat and fibre intake [27]
 The Health State Descriptive System to assess
quality of life, known as 15D [28]
 The Hospital Anxiety and Depression HADS –
validated for depression and anxiety relating to
diagnosis of condition and the care provided
thereafter [29]
 The Brief Illness Perception Questionnaire or BIPQ
designed to quickly assess cognitive and emotional
representations of illness [30]
 The International Physical Activity Questionnaire
(short form) (IPAQ) to obtain internationally
comparable data on health–related physical activity
[31]
Patients will also self-report on two questions concern-
ing sleeping pattern (how many hours sleep did you get
last night? And on average, how many hours do you
sleep in 24 hours) [32].
Outcomes
The primary outcome of the screening phase is the pro-
portion of people detected with IGR or T2DM using a
validated risk tool (positive predictive value). Secondary
outcomes include the response rate to the invitation to
screening. Those with IGR will be asked if they would
like to take part in phase 2 – the diabetes prevention
cluster randomised controlled trial.
Phase 2: Cluster randomised trial
Phase 2 is designed to adhere to internationally recog-
nised criteria for developing complex interventions and
for undertaking and reporting cluster randomised con-
trolled trials [33]. Randomisation will be conducted at
the level of the GP practice by a researcher who is inde-
pendent of the study team. Cluster designs are being
used in other similar trials of lifestyle management inter-
ventions [34–36]. Practices will be randomised 1:1 to ei-
ther the control arm or the intensive arm using
stratification by list size (<6,000, ≥6,000), and ethnicity
(% South Asian <21%, ≥21% (median level of % South
Asian in the ADDITION-Leicester study [37]) with a
block size of 4.
Participation in the study is summarised in Figure 1. A
summary of the data collected at each time point is given
in Table 1. The primary outcome data will be collected
at 36 months. Additional data will be collected at 6, 12
Figure 1 Study participation.
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standard operating procedures as the baseline/screening
data described in Phase 1. Additionally at the 3 year fol-
low up a health resource one page questionnaire and the
EQ-5D will be collected [38]. Records are kept on missed
clinical visits; structured education programmes and tele-
phone support as well as withdrawn subjects.
Inclusion criteria
Patients who were eligible for phase 1 are included in
the trial if
 Diagnosed with IGR (IGT and/or IFG) at the OGTT
at screening/baseline visit
Exclusion criteria
Patients are excluded from the trial if they are:
 Diagnosis of diabetes at screening/baseline (if
diagnosed during the study participants are invited
to continue without the 120 glucose sample or
further intervention activities)
Control arm intervention
Control subjects receive a booklet detailing information on
risk factors for T2DM and how physical activity and lifestyle
change can be used to prevent or delay the disease. The
leaflet addresses factors around T2DM risk using the five
domains (causes, consequences, identity, control/treatment,and timeline) highlighted by Leventhal’s common sense
model [39]. The follow up sessions for the control group
will occur at the same time points as the intervention group
and the same data will be collected.
Intensive arm intervention
Participants in this arm receive the same information
booklet as the control arm and in addition are invited to
attend an initial six hour structured education
programme called Lets Prevent (LP), three monthly
nursing support phone calls, and a yearly three hour up-
date structured education programme.
The style, content and process of the programme
draws on a range of concepts from health psychology
and education [39–42] and its philosophy is centred on
patient empowerment [43]. In short, it is a six hour
group based education programme that can be either
delivered in one full six hour day or in two three hour
sessions. The programme has a written curriculum, an
outline of which can be seen in Table 2. The key food
messages are taken from the Diabetes Prevention Pro-
gram [44] and the Finnish Prevention Study [45]. Goals
are to attain a sustained weight reduction of greater than
5% body weight, moderate reduction in total fat of less
than 30% energy intake, low saturated fat intake of less
than 10% energy intake and higher fibre intakes of
greater than 15 g per 1,000 calories.
The physical activity messages are taken from the
Pre-diabetes Risk Education and Physical activity













Medical History X X X X
Medication History X X X X
Physical Exam X X X X
Cardiovascular
Risk Score




X X X X X
Anthropometric
3 x Blood Pressure X X X X X
Height X X
Weight X X X X X
Waist
Circumference




X X X X
HbA1c X X X X X
Lipids X X X X X
Urea & Electrolytes X X X X
Liver Function Tests X X X X
Questionnaires & Lifestyle Measures
IPAQ – SF [31] X X X X X
DINE [27] X X X X X
BIPQ [30] X X X X X
HADS [29] X X X X X
15D [28] X X X X X
Health care resource use X
EQ-5D [38] X
Sleep questions X X X X X
7 Day Step Count X X X X X
Urine Sample X X X X
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PARE) [12,13]. The PREPARE programme successfully
demonstrates that a pragmatic education programme that
incorporates pedometer use is effective in improving glu-
cose tolerance in those with IGT. As in the PREPARE
programme, participants are provided with a pedometer as
a tool for promoting self-regulatory strategies such as goal
setting and self-monitoring. The physical activity goal is to
achieve an increase in daily walking of 45 minutes or 4,500
steps. Goal attainment is encouraged through the use of
proximal objectives such as increasing steps by 500 per
day every two weeks.
Following 12 and 24 month clinic appointments, parti-
cipants are offered the option of attending a three hourupdate session. The purpose of this update session is to
review key messages, review personal risk and action
plan. Throughout the three year intervention, partici-
pants receive three monthly telephone contacts from
nurses trained to support participants with their chosen
behaviour change. A quality development programme
ensures that the educational intervention is delivered in
such a way that the core content and learning outcomes
are achieved and the educator behaviours are linked to
the programme philosophy and learning theories. The
quality development programme consists of internal and
external processes adapted from findings from the DES-
MOND collaborative [46].
Methodologies previously used to effectively modify
the DESMOND module to be suitable for those from
Black and Minority Ethnic (BME) groups were used to
develop the LP BME intervention [47]. The core educa-
tional messages are the same as in LP but the
programme is culturally appropriate and non reliant on
the written word. The LP BME programme is delivered
as four sessions of three hours if delivered with an inter-
preter or two three hour sessions without an interpreter.
Endpoints and outcomes
The primary outcome aims to show the reduction in the in-
cidence of T2DM at 36 months in people with screen-
detected IGR. Secondary outcomes are reductions in
HBA1c, blood glucose levels fasting and post glucose load,
cardiovascular risk as calculated by the Framingham risk
calculator [48] and the presence of Metabolic Syndrome as
defined by NCEP ATP III [49], increasing seven day step
count and cost-effectiveness of the intervention.
Power calculation
Assuming a 3 year cumulative conversion rate to T2DM
of 35% in the control group [44,45,50], an intra class
correlation of 0.05 and a dropout rate of 20% (as seen in
the Finnish Prevention Study [51]), we calculated that
we would need 374 patients to consent per group to de-
tect a 40% risk reduction in the intervention group –
data from 44 practices, 17 participants per practice, with
80% power at the 5% significance level. For 17 partici-
pants to be recruited per practice we have assumed a
participation rate of around 20%. For an average practice
500 people will be invited for screening, of these around
20% will have pre-diabetes (assuming a positive predict-
ive value of 20% [24]). Therefore around 100 partici-
pants per practice will be eligible for the trial. Assuming
a participation rate of 20% should give the 17 partici-
pants we need per practice. A participation rate of 20%
has been seen in other studies in a similar population
[19].
A 40% reduction in the relative risk of developing
T2DM was chosen as a conservative interpretation of
Table 2 The Lets Prevent curriculum content
Session 1 Theory Sample Activity Duration
Introduction - - 10 mins
Patient story CSM Participants asked to tell their story about how they discovered they
had pre diabetes and their current knowledge of pre diabetes
30 mins





CSM, DPT, SLT Uses participants’ stories to support them in discovering how
weight/waist affects pre diabetes. Provides knowledge and skills
for food choices to control weight
30 mins
Physical activity CSM, DPT, SLT Uses participants’ stories to support them in discovering how physical
activity affects pre diabetes. Provides knowledge and skills for activity
choices to manage pre diabetes
40 mins
How am I doing? SLT Participants reflect on what issues have come up in the programmes so far 5 mins
Session 2 Theory Sample Activity Duration
Reflections SLT Participants reflect issues that have arisen in the programme so far 10 mins
Professional story CSM Uses participants’ stories to support them in discovering how other risk
factors (e.g. blood pressure and cholesterol) affect pre diabetes and





DPT, SLT Provides knowledge and skills for food choices to reduce risk factors 50 mins
Self management plan SLT Participants supported in developing their self management plans 30 mins
Questions CSM Checks that all questions raised by participants throughout the
programme have been answered and understood
40 mins
What happens next? SLT Follow up care outlines 5 mins
CSM: Common sense model, DPT: Dual processing theory, SLT: Social learning theory.
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tematic review have shown that lifestyle intervention
studies in those with IGT resulted in a ~50% reduction
in the relative risk of developing T2DM [5,52,53]. An
intention to treat analysis of 12-month follow-up data
from a randomised controlled trial found that an inter-
vention aimed at the promotion of physical activity,
using methods that are similar to the proposed study,
achieved a reduction in 2-hour glucose of 1.3 mmol/l
compared to the control group [12]. A reduction of 2-
hour glucose of this magnitude has been associated with
around a 50% reduction in the relative risk of developing
T2DM [52], which is consistent with the above evidence.
One secondary outcome will be the percentage of
patients in each group with a 10-year CVD risk greater
than 20% at end of 3 years. It is estimated that 55% of
patients will have a CV risk greater than 20%. To detect
a difference between the two groups of 20% points in the
proportion of patients with a 10 year risk of >20% with
80% power and two alpha of 5% and an intra-practice
correlation coefficient of 0.05 the required sample size is
180 in the two groups.
Data analysis
At major time points and at study completion the find-
ings will be reported according to the internationallyrecognised CONSORT statement for the reporting of
cluster randomised control trials [54]. Data will be ana-
lysed on an intention to treat basis (ITT). Data will be
analysed using STATA v10, and all analysis will take into
account the clustering by GP practice. Survival curves
would be calculated to estimate the cumulative incidence
of diabetes. The difference in incidence of T2DM in the
groups is tested using the two-sided log-rank test
adjusted for cluster. Differences in secondary outcomes
between the groups will be assessed using either linear
for continuous outcomes or logistic for categorical out-
comes regression with treatment group as the independ-
ent variable.
Health economics
An economic evaluation will be conducted alongside the
study. The objective will be to estimate the cost-effect-
iveness of the educational intervention compared to con-
trol. Resource use, costs and health outcomes will be
measured in each arm of the study, and cost-effective-
ness will be calculated as the difference in costs divided
by the difference in effects. Costs will include the costs
of the initial and ongoing intervention, drug use, all
health care consultations and visits, and hospitalisations.
These will be collected directly from the participants
using the using from trial case record forms (for
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page) questionnaire given to all patients at the final (36-
month) visit, which will also record patient incurred
costs. Effectiveness will be measured as 1) incidence of
T2DM at 36 months, in line with the primary outcomes,
and 2) quality adjusted life years gained. Within-trial
quality of life will be measured using the 15D instrument
at baseline and all follow-up points, and the EQ-5D at
the final visit [38]. Long-term cost-effectiveness will be
estimated by extrapolating from 36 months using the
Framingham risk equation. Predictions for patients with
diagnosed diabetes will be cross-checked using the
UKPDS Outcomes Model. Uncertainty around all esti-
mates will be fully reported using recommended para-
metric and non-parametric methods, with additional
sensitivity analyses for areas of methodological or policy
uncertainty. If the intervention appears cost-effective in
the trial comparison, the likely screening costs in normal
practice (rather than the screening costs in the trial,
which may include protocol-driven elements) will also be
estimated and included. We will undertake a subsidiary
analysis on differences by allocation in changes in em-
ployment hours, nature or status using self reported data
collected at baseline, 6 months and the annual follow
ups.
Funding and timescale
The project is funded by an NIHR Programme Grant.
Screening started in July 2009 and the last patient should
attend their last follow up in July 2014.
Discussion
To our knowledge this will be the first study in the Uni-
ted Kingdom to establish the long-term effectiveness of
an intervention structured education programme to pro-
mote lifestyle change in those with a high risk of T2DM
identified using a risk score. This complete programme
of screening for high risk individuals followed by a life-
style modification intervention is in line with the recom-
mendations from the IMAGE project [55]. Whilst both
the effectiveness and cost-effectiveness of structured
education programmes at preventing T2DM has been
established, there has been a lack of translational re-
search aimed at patients at risk and/or with IGR, specif-
ically designed for a routine health care setting in the
UK. This study will help address this limitation and aims
provide an effective solution to this need.
The Let’s Prevent programme was specifically designed
for translation into routine care. Structured education is
already recommended by NICE for promoting a healthy
lifestyle and self-management in those with diagnosed
T2DM and has a track record of implementation and de-
livery in usual health care practice spanning the last dec-
ade. For example, the DESMOND programme, on whichthe structure and underlying philosophy of Let’s Prevent
is based, is delivered in over half of all primary care orga-
nisations nationally and is supported by an established
infrastructure for training and quality assuring educators
at a national level [46,56]. Let’s Prevent was designed to
be suitable for integration into these types of existing
platforms for the delivery of structured education in pri-
mary care. This will allow primary care organisations to
commission a suite of structured education programmes
to meet the needs of their diabetes pathways. This is par-
ticularly relevant to current health care policy in the
United Kingdom, where the prevention of diabetes and
other chronic diseases is actively targeted and supported
through the NHS Health Checks Programme [57]. NICE
have also recently drafted guidance around the preven-
tion of diabetes [58]. These policies and recommenda-
tions advocate the use lifestyle interventions for high risk
patients as the central pillar of any diabetes prevention
pathway. Therefore, it is important that commissioning
groups have access to intervention programmes that
have been rigorously evaluated for effectiveness and
cost-effectiveness and which are suitable for direct trans-
lation into a routine primary care setting.
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